182 related articles for article (PubMed ID: 31565143)
21. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
[TBL] [Abstract][Full Text] [Related]
22. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
[TBL] [Abstract][Full Text] [Related]
23. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
24. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
Block GA; Hulbert-Shearon TE; Levin NW; Port FK
Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
[TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics of Patients on Long-term Hemodialysis.
Hamid A; Dhrolia MF; Qureshi R; Imtiaz S; Ahmad A
J Coll Physicians Surg Pak; 2019 Apr; 29(4):328-332. PubMed ID: 30925954
[TBL] [Abstract][Full Text] [Related]
26. Status of Serum Calcium, Phosphate and Intact Parathyroid Hormone in Predialysis Chronic Kidney Disease Patients of Stage-3 to Stage-5 Compared To KDOQI Guideline.
Hai AA; Rahman MM; Anwar MR; Miah OF; Latif A; Jalil ME; Razzak MA; Morshed AM; Mahmud H; Dowel FA
Mymensingh Med J; 2021 Oct; 30(4):1031-1042. PubMed ID: 34605474
[TBL] [Abstract][Full Text] [Related]
27. Short- and long-term impact of subtotal parathyroidectomy on the achievement of bone and mineral parameters recommended by clinical practice guidelines in dialysis patients: a 12-year single-center experience.
Tsai WC; Peng YS; Yang JY; Hsu SP; Wu HY; Pai MF; Chang JF; Chen HY
Blood Purif; 2013; 36(2):116-21. PubMed ID: 24217122
[TBL] [Abstract][Full Text] [Related]
28. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?
Deger SM; Mutluay R; Derici U; Mandiralioglu F; Arinsoy T; Sindel S
Med Princ Pract; 2011; 20(1):85-9. PubMed ID: 21160221
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
[TBL] [Abstract][Full Text] [Related]
30. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
Moe SM; Chertow GM; Coburn JW; Quarles LD; Goodman WG; Block GA; Drüeke TB; Cunningham J; Sherrard DJ; McCary LC; Olson KA; Turner SA; Martin KJ
Kidney Int; 2005 Feb; 67(2):760-71. PubMed ID: 15673327
[TBL] [Abstract][Full Text] [Related]
31. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
[TBL] [Abstract][Full Text] [Related]
32. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
33. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
34. Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015).
Al Salmi I; AlRukhaimi M; AlSahow A; Shaheen FA; Al-Ghamdi SM; AlAli F; AlGhareeb S; Al Maimani Y; AlGhonaim M; Bieber B; Tentori F; Pisoni RL;
Saudi J Kidney Dis Transpl; 2016 Nov; 27(6 Suppl 1):62-80. PubMed ID: 27991480
[TBL] [Abstract][Full Text] [Related]
35. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study.
Qunibi WY; Nolan CR
Kidney Int Suppl; 2004 Sep; (90):S33-8. PubMed ID: 15296505
[TBL] [Abstract][Full Text] [Related]
36. Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.
Kovacevic B; Ignjatovic M; Zivaljevic V; Cuk V; Scepanovic M; Petrovic Z; Paunovic I
Langenbecks Arch Surg; 2012 Mar; 397(3):413-20. PubMed ID: 22240976
[TBL] [Abstract][Full Text] [Related]
37. Low-calcium dialysate improves mineral metabolism in hemodialysis patients.
Fujimori A; Yorifuji M; Sakai M; Oyama M; Nakao N; Tokuyama M; Fukagawa M
Clin Nephrol; 2007 Jan; 67(1):20-4. PubMed ID: 17269595
[TBL] [Abstract][Full Text] [Related]
38. Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients.
Lorenzo V; Martín M; Rufino M; Jiménez A; Malo AM; Sanchez E; Hernández D; Rodríguez M; Torres A
Am J Kidney Dis; 2001 Jun; 37(6):1260-6. PubMed ID: 11382697
[TBL] [Abstract][Full Text] [Related]
39. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients.
Johansen KL; Chertow GM
J Ren Nutr; 2007 Sep; 17(5):305-13. PubMed ID: 17720099
[TBL] [Abstract][Full Text] [Related]
40. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
